Biopharmaceuticals Archives – DHbriefs https://dhbriefs.com/cat_section/biopharmaceuticals/ All about the European digital health ecosystem Wed, 28 Jun 2023 06:56:42 +0000 en-US hourly 1 https://wordpress.org/?v=6.8.5 Tagworks Pharmaceuticals https://dhbriefs.com/dbentry/tagworks-pharmaceuticals/ Wed, 28 Jun 2023 06:56:42 +0000 https://dhbriefs.com/?post_type=dbentry&p=9655 Tagworks Pharmaceuticals is a precision therapy company and a pioneer of the Click-to-Release approach. Leveraging its patent-protected technology platform, it aims to create a new standard of care for patients suffering from severe diseases, including cancer. With operations in the Netherlands and the U.S., Tagworks is developing a pipeline of click-cleavable therapies. Its lead program, ...

The post Tagworks Pharmaceuticals appeared first on DHbriefs.

]]> Tagworks Pharmaceuticals is a precision therapy company and a pioneer of the Click-to-Release approach. Leveraging its patent-protected technology platform, it aims to create a new standard of care for patients suffering from severe diseases, including cancer. With operations in the Netherlands and the U.S., Tagworks is developing a pipeline of click-cleavable therapies. Its lead program, TGW101, is an antibody-drug conjugate (ADC) targeting TAG72 — a clinically-validated, pan-carcinoma target that so far has remained out of reach of current ADC therapies. Tagworks’ technology enables on-target activation of ADCs and immunomodulators, as well as off-target deactivation of radioimmunotherapies to enhance their therapeutic index.

The post Tagworks Pharmaceuticals appeared first on DHbriefs.

]]> T-knife Therapeutics https://dhbriefs.com/dbentry/t-knife-therapeutics/ Sun, 04 Jun 2023 18:52:57 +0000 https://dhbriefs.com/?post_type=dbentry&p=9507 T-knife is a next-generation T-cell receptor (TCR) company developing a pipeline of therapeutics for solid tumor patients. The company leverages its proprietary humanized T-cell receptor (HuTCR) mouse platform to produce fully human TCRs, naturally selected in vivo for optimal affinity and specificity. T-knife is developing a pipeline of potential first/best-in-class TCR therapeutics against targets with ...

The post T-knife Therapeutics appeared first on DHbriefs.

]]> T-knife is a next-generation T-cell receptor (TCR) company developing a pipeline of therapeutics for solid tumor patients. The company leverages its proprietary humanized T-cell receptor (HuTCR) mouse platform to produce fully human TCRs, naturally selected in vivo for optimal affinity and specificity. T-knife is developing a pipeline of potential first/best-in-class TCR therapeutics against targets with high unmet medical need, including cancer testis antigens, viral antigens and commonly shared neoantigens. In addition to Berlin, the company also has an office in San Francisco.

The post T-knife Therapeutics appeared first on DHbriefs.

]]> AM-Pharma https://dhbriefs.com/dbentry/am-pharma/ Wed, 05 Oct 2022 08:08:36 +0000 https://dhbriefs.com/?post_type=dbentry&p=8289 AM-Pharma is a clinical-stage biopharmaceutical company developing a treatment for sepsis-associated acute kidney injury (SA-AKI) – recombinant human alkaline phosphatase therapeutic. The company is focused on the successful execution of its Phase III REVIVAL pivotal trial while continuing to build an organization committed to using its insight and knowledge for other severe medical conditions, including ...

The post AM-Pharma appeared first on DHbriefs.

]]> AM-Pharma is a clinical-stage biopharmaceutical company developing a treatment for sepsis-associated acute kidney injury (SA-AKI) – recombinant human alkaline phosphatase therapeutic. The company is focused on the successful execution of its Phase III REVIVAL pivotal trial while continuing to build an organization committed to using its insight and knowledge for other severe medical conditions, including other kidney diseases, sepsis and organ injury-related indications.

The post AM-Pharma appeared first on DHbriefs.

]]>